<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02968901</url>
  </required_header>
  <id_info>
    <org_study_id>AC-055-405</org_study_id>
    <nct_id>NCT02968901</nct_id>
  </id_info>
  <brief_title>Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)</brief_title>
  <acronym>OPTIMA</acronym>
  <official_title>Prospective, Multicenter, Open-label Study Evaluating the Effects of First-line Oral Combination Therapy of Macitentan and Tadalafil in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (OPTIMA).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to document the effect of first line dual oral combination
      therapy with macitentan 10mg and tadalafil 40mg on pulmonary vascular resistance (PVR) in
      treatment-naïve patients with newly diagnosed pulmonary arterial hypertension (PAH).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2015</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pulmonary vascular resistance (PVR)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change from Baseline to Week 16 in percentage of patients with clinically meaningful improvement of PVR (decrease of 30% from baseline to Week 16)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean right atrial pressure (mRAP)</measure>
    <time_frame>Week 16</time_frame>
    <description>Change from Baseline to Week 16 in mean right atrial pressure (mRAP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6MWD</measure>
    <time_frame>Week 16</time_frame>
    <description>Change from Baseline to Week 16 in 6MWD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level NT-proBNP</measure>
    <time_frame>Week 16</time_frame>
    <description>Change in NT-proBNP from baseline to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean pulmonary arterial pressure (mPAP)</measure>
    <time_frame>Week 16</time_frame>
    <description>Change from Baseline to Week 16 in mean pulmonary arterial pressure (mPAP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac index (CI)</measure>
    <time_frame>Week 16</time_frame>
    <description>Change from Baseline to Week 16 in cardiac index (CI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total pulmonary resistance (TPR)</measure>
    <time_frame>Week 16</time_frame>
    <description>Change from Baseline to Week 16 in total pulmonary resistance (TPR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mixed venous oxygen saturation (Sv02)</measure>
    <time_frame>Week 16</time_frame>
    <description>Change from Baseline to Week 16 in mixed venous oxygen saturation (Sv02)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO functional class</measure>
    <time_frame>Week 16</time_frame>
    <description>Change from baseline to Week 16 in WHO functional class and Percentage of patients with improvement/worsening of WHO functional class from baseline to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment goals</measure>
    <time_frame>Week 16</time_frame>
    <description>Number of treatment goals (score 0 or 1 per goal, i.e. total score 0-5) met at Week 16: WHO-FC I or II; Cardiac index &gt; 2.8 L/min/m²; mRAP &lt; 8 mmHg; 6MWD &gt; 400 m; NT-proBNP &lt; 3xULN</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>bitherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Macitentan and tadalafil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>macitentan</intervention_name>
    <description>used in open label</description>
    <arm_group_label>bitherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil</intervention_name>
    <description>used in open label</description>
    <arm_group_label>bitherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          1. Signed informed consent prior to any study-mandated procedure.

          2. Male or female ≥ 18 and ≤ 75 years of age at screening.

          3. Initial PAH diagnosis &lt; 6 months prior to Day 1.

          4. Right heart catheterization (RHC) performed between Day -28 and Day 1 (RHC data
             obtained at the study site within this time frame, but before the study, i.e., before
             signed informed consent, are acceptable), meeting all the following criteria:

               -  Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg.

               -  Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic
                  pressure (LVEDP) ≤ 15 mmHg.

               -  PVR ≥ 400 dyn·sec/cm5 (≥ 5 Wood units) if PCWP &lt; 12 mmHg OR PVR ≥ 500 dyn·sec/cm5
                  (≥ 6.25 Wood units) if PCWP in [12-15] mmHg.

               -  Negative vasoreactivity test mandatory in idiopathic PAH (at this or a previous
                  RHC).

          5. World Health Organization (WHO) Functional Class (FC) II to III.

          6. PAH etiology belonging to one of the following groups:

               -  Idiopathic.

               -  Heritable.

               -  Anorexigens induced.

               -  Associated with one of the following:

                    -  Connective tissue disease

                    -  Congenital heart disease with simple systemic-to-pulmonary shunt (atrial
                       septal defect, ventricular septal defect, patent ductus arteriosus) ≥1 year
                       after surgical repair

                    -  HIV infection

          7. 6MWD ≥ 50 m at screening.

          8. Woman of childbearing potential [see definition in Section 4.5.1] must:

               -  Have a negative serum pregnancy test at the screening visit and a negative urine
                  pregnancy test at the D1 visit, and

               -  Agree to perform monthly pregnancy tests up to 30 days after EOT2, and

               -  Agree to use reliable contraception [defined in Section 4.5.2] from screening up
                  to 30 days after EOT2. Reliable contraception must be started at least 11 days
                  prior to Day 1.

        Exclusion Criteria:

          1. Any PAH-specific drug therapy [e.g. any endothelin receptor antagonist,
             phosphodiesterase-5 inhibitors (PDE-5i), soluble guanylate cyclase stimulator,
             prostacyclin, prostacyclin analog, or prostacyclin receptor agonist] at any time prior
             to Day 1 (single-dose administration for vasoreactivity testing is permitted; previous
             iloprost used intermittently for the treatment of digital ulcers or Raynaud's
             phenomenon is permitted if stopped &gt; 6 months prior to Day 1).

          2. Subjects who changed the dose or discontinued calcium channel blockers within 1 week
             prior to Day 1.

          3. Initiation of diuretics within 1 week prior to RCH.

          4. Subjects on oral diuretics in whom the dose has not been stable for at least 1 week
             prior to RHC.

          5. Treatment with other PDE-5i for erectile dysfunction.

          6. Treatment with strong inducers of CYP3A4 (e.g., carbamazepine, rifampin, rifampicin,
             rifabutin, rifapentin, phenobarbital, phenytoin, and St. John's wort) ≤ 28 days prior
             to Day 1.

          7. Treatment with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole,
             voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, boceprevir,
             telaprevir, saquinavir, lopinavir, fosamprenavir, darunavir, tipranavir, atazanavir,
             nelfinavir, amprenavir, indinavir) ≤ 28 days prior to Day 1.

          8. History of priapism.

          9. Significant aortic and mitral valve disease requiring a specific treatment.

         10. Pericardial constriction.

         11. Life-threatening arrhythmia.

         12. Uncontrolled hypertension.

         13. Symptomatic coronary artery disease.

         14. Cardio-pulmonary rehabilitation program based on exercise (planned, or started ≤ 12
             weeks prior to Day 1).

         15. Body mass index (BMI) &gt; 40 kg/m2 at screening.

         16. Acute myocardial infarction ≤ 12 weeks prior to Day 1.

         17. Known permanent atrial fibrillation.

         18. Low blood pressure &lt; 90/50 mmHg at screening or Day 1.

         19. Ongoing or planned treatment with nitrates and/or doxazosin.

         20. DLCO &lt; 40% of predicted value (eligible only if no sign of veno-occlusive disease
             according to adjudication committee);

         21. Presence of ≥ 1 of the following signs of relevant lung disease at any time prior to
             Day 1:

               -  FEV1/FVC &lt; 70% and FEV1 &lt; 65% of predicted after bronchodilator administration;

               -  Total Lung Capacity (TLC) &lt; 60% of predicted.

         22. Known or suspicion of pulmonary veno-occlusive disease (PVOD).

         23. Severe renal insufficiency (estimated creatinine clearance ≤ 30 mL/min/1.73m²)
             assessed by central laboratory at screening.

         24. Ongoing or planned dialysis.

         25. Documented severe hepatic impairment (with or without cirrhosis) according to National
             Cancer Institute organ dysfunction working group criteria, defined as total bilirubin
             &gt; 3 x ULN accompanied by AST &gt; ULN (assessed by central laboratory at screening)
             and/or Child-Pugh Class C.

         26. Serum AST and/or ALT &gt; 3 x ULN (assessed by central laboratory at screening).

         27. Porto-pulmonary hypertension.

         28. Hemoglobin &lt; 100 g/L assessed by central laboratory at screening.

         29. Hypersensitivity to any active substance or excipient of macitentan or tadalafil
             formulation.

         30. Loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy
             (NAION), regardless of whether or not this episode was in connection with previous
             PDE-5i exposure.

         31. Hereditary degenerative retinal disorders, including retinitis pigmentosa.

         32. Pregnancy, breast-feeding, intention to become pregnant during the study or woman of
             childbearing potential not agree to use reliable method of contraception from
             screening up to 30 days after EOT2.

         33. Hereditary problems of galactose intolerance, Lapp lactase deficiency,
             glucosegalactose malabsorption.

         34. Any factor or condition likely to affect protocol compliance of the patient as judged
             by the investigator.

         35. Treatment with another investigational drug (planned, or taken ≤ 12 weeks prior to Day
             1).

         36. Concomitant life-threatening disease with a life expectancy &lt; 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Isabelle Aub&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#233;, Doctor</last_name>
    <email>isabelle.aube@actelion.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Degano, Doctor</last_name>
      <email>degano.b@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de Haut Levêque</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Picard, Doctor</last_name>
      <email>francois.picard@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Claire Dromer</last_name>
      <email>claire.dromer@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Bergot</last_name>
      <email>bergot-e@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Site du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Favrolt, Doctor</last_name>
      <email>nicolas.favrolt@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Pison, Doctor</last_name>
      <email>cpison@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicètre</name>
      <address>
        <city>Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Jais, doctor</last_name>
      <email>xavier.jais@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Palat, Doctor</last_name>
      <email>sylvain.palat@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Cottin, Doctor</last_name>
      <email>vincent.cottin@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Timone Adultes</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien Renard, Doctor</last_name>
      <email>sebastien.renard@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34929</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud Bourdin</last_name>
      <email>a-bourdin@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR La Miletrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-claire Simon, Doctor</last_name>
      <email>Simon.anneclaire@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amélie Servettaz, doctor</last_name>
      <email>aservettaz@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline Chabanne, doctor</last_name>
      <email>celine.chabanne@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice Bauer, Doctor</last_name>
      <email>fabrice.bauer@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42277</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Bertoletti, Doctor</last_name>
      <email>laurent.bertoletti@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthieu Canuet, Doctor</last_name>
      <email>matthieu.canuet@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grégoire Prévot, Doctor</last_name>
      <email>prevot.g@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Magro, Doctor</last_name>
      <email>magro@med.univ-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2016</study_first_submitted>
  <study_first_submitted_qc>November 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2016</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Macitentan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

